Aim: This executive summary of the valvular heart disease guideline provides recommendations for clinicians to diagnose and manage valvular heart disease as well as supporting documentation to encourage their use.
Methods: A comprehensive literature search was conducted from January 1, 2010, to March 1, 2020, encompassing studies, reviews, and other evidence conducted on human subjects that were published in English from PubMed, EMBASE, Cochrane, Agency for Healthcare Research and Quality Reports, and other selected database relevant to this guideline.
Structure: Many recommendations from the earlier valvular heart disease guidelines have been updated with new evidence and provides newer options for diagnosis and treatment of valvular heart disease. This summary includes only the recommendations from the full guideline which focus on diagnostic work-up, the timing and choice of surgical and catheter interventions, and recommendations for medical therapy. The reader is referred to the full guideline for graphical flow charts, text, and tables with additional details about the rationale for and implementation of each recommendation, and the evidence tables detailing the data considered in developing these guidelines.
Keywords: AHA Scientific Statements; anticoagulation therapy; aortic regurgitation; aortic stenosis; bicuspid aortic valve; cardiac surgery; infective endocarditis; mitral regurgitation; mitral stenosis; mitral transcatheter edge-to-edge repair; prosthetic valve; pulmonic regurgitation; pulmonic stenosis; transcatheter aortic valve replacement or implantation; tricuspid regurgitation; tricuspid stenosis; valvular heart disease.
Copyright © 2021 American College of Cardiology Foundation and the American Heart Association, Inc. Published by Elsevier Inc. All rights reserved.